Actinium Pharmaceuticals Inc (ATNM) Sees Large Growth in Short Interest

Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) saw a large growth in short interest during the month of January. As of January 31st, there was short interest totalling 2,119,750 shares, a growth of 11.3% from the January 15th total of 1,905,313 shares. Currently, 1.9% of the company’s stock are short sold. Based on an average daily trading volume, of 730,597 shares, the short-interest ratio is currently 2.9 days.

ATNM traded up $0.01 during mid-day trading on Monday, reaching $0.53. 271,200 shares of the stock were exchanged, compared to its average volume of 521,293. Actinium Pharmaceuticals has a 1 year low of $0.33 and a 1 year high of $0.87.

Several large investors have recently modified their holdings of the company. Virtu Financial LLC lifted its position in shares of Actinium Pharmaceuticals by 103.1% during the 3rd quarter. Virtu Financial LLC now owns 195,623 shares of the biotechnology company’s stock valued at $146,000 after buying an additional 99,318 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Actinium Pharmaceuticals by 6.4% during the 3rd quarter. Vanguard Group Inc. now owns 2,575,754 shares of the biotechnology company’s stock worth $1,909,000 after purchasing an additional 154,403 shares during the last quarter. Vanguard Group Inc increased its position in Actinium Pharmaceuticals by 6.4% during the 3rd quarter. Vanguard Group Inc now owns 2,575,754 shares of the biotechnology company’s stock valued at $1,909,000 after buying an additional 154,403 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Actinium Pharmaceuticals by 23.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 1,031,210 shares of the biotechnology company’s stock valued at $399,000 after purchasing an additional 198,480 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in shares of Actinium Pharmaceuticals by 1,269.5% in the second quarter. Renaissance Technologies LLC now owns 387,500 shares of the biotechnology company’s stock worth $248,000 after buying an additional 359,205 shares during the last quarter.

Several equities research analysts have recently commented on the company. Maxim Group set a $3.00 price target on Actinium Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, December 3rd. Oppenheimer set a $5.00 price target on shares of Actinium Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, November 28th. Roth Capital set a $6.00 price target on shares of Actinium Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, November 8th. Finally, Zacks Investment Research downgraded shares of Actinium Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, December 3rd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Actinium Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $3.55.

ILLEGAL ACTIVITY WARNING: This story was reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.themarketsdaily.com/2019/02/12/actinium-pharmaceuticals-inc-atnm-sees-large-growth-in-short-interest.html.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.

Read More: What is a Swap?

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply